Symptoms for neuroendocrine tumours (NETs) include fatigue, flushing, heart palpitations, an upset stomach and bowel symptoms.
Unfortunately NETs are difficult to diagnose because the symptoms are common across many illnesses, and treatments vary depending on where the tumour is located, how many there are, pace of growth and more.
The Hospital Research Foundation Group is proud to support the Nuclear Medicine Department at The Queen Elizabeth Hospital as a leader in the treatment of neuroendocrine tumours by providing patients access to world-leading clinical trials and research.
Neuroendocrine Tumour Support
Supporting The Queen Elizabeth Hospital’s nuclear medicine and oncology teams offer new therapies such as LuTate Therapy (also known as Peptide Receptor Radionuclide Therapy) and Rose Bengal.
Establishing a local data registry to capture clinical and quality-of-life data on recipients of LuTate Therapy, evaluating treatment success, toxicity, late complications, overall survival and quality of life.
Coordinating a wellness and survivorship program tailored around each patient’s unique circumstances, ensuring there is concise communication about the services available to patients, personalised patient schedules and education around self-management and wellbeing.